NY-PHILIP-MORRIS-INTL
24.9.2020 21:22:05 CEST | Business Wire | Press release
André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit . Calantzopoulos discussed the impact that uncertainty, polarization, hyperpartisanship, and ideology are having on international efforts to overcome pressing global issues. He called for science to be protected from politicization and highlighted the importance of developing open dialogues based on factual scientific objectivity. Calantzopoulos shared PMI’s belief that with the right regulatory encouragement and support from civil society, cigarette sales can end within 10 to 15 years in many countries.
The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.
Excerpts of the remarks by André Calantzopoulos follow:
“Reflecting on the state of our world today and the challenges ahead, four words come to mind: Uncertainty . Polarization. Hyperpartisanship. Ideology.
“These words are not new, but with the COVID crisis, they have gained prominence, moving beyond traditionally contentious sectors such as ours and into the mainstream.
“The lockdowns that sent us into our homes earlier this year, the continued uncertainty we all feel, and the immense socioeconomic pressure caused by the pandemic have increased tensions and reinforced the polarization of both private views and the public discourse.
“And while these past months have revealed how much can be accomplished when people work together, the tendency of individuals to put their self-centered impulses ahead of community wellness remains on display.
“Divisiveness—a binary choosing of sides—not only hinders progress but threatens to thwart it.
“Maybe there is no silver-bullet solution—but to focus on respect for and adherence to facts, dialogue, inclusion, and science could help immensely. It is not enough, however, to simply say ‘follow the facts and the science’ and expect progress to unfold. COVID-19 is just the latest example that proves a tragic truth: Science can be, and is being, weaponized to suit narrow agendas. Science and facts are being held hostage—and distorted—by politics, and people are suffering as a result.
“As a society, we are experiencing a confluence of global existential threats. These threats require collective, multilateral discussions and cooperation—and that can only be achieved through a commitment to open dialogue.
“Absent a commitment to factual scientific objectivity—free of agenda-driven politics—we risk the very real and terrifying prospect of vaccine nationalism, an inability to tackle climate change at scale, and a narrowed chance of delivering solutions that create a fairer and more equitable world.
“In a global world, in a global economic and human system, whether we like it or not, there is no solution in isolation. Individual governments or companies alone cannot bring the necessary change. If we want to make the United Nations Sustainable Development Goals a reality, if we want to protect our populations from the pandemic, including implementing a viable vaccine, we must work together. And most important, we must involve the 7.8 billion people on this planet. How do we do this? We tell them what the real problems are—offering the full facts; we propose solutions they can adopt or adapt; and we incentivize them to act in accordance with this new knowledge. We won’t succeed by keeping them in the dark, by confusing them, or by misleading them.
“Being at the helm of the largest multinational tobacco company as it transforms to deliver a smoke-free future, I experience firsthand how detrimental polarization is to making real progress—in this case, progress in eradicating smoking. And, as a reminder, this concerns more than 1 billion men and women who smoke around the world.
“Today, science-based, innovative products that do not involve combustion offer a better alternative for those men and women who would otherwise continue to smoke. To be clear: These products are not risk-free. And the best choice is never to start smoking or to quit tobacco and nicotine altogether. But for those adults who would otherwise continue to smoke, scientifically validated smoke-free products are a much better choice than cigarettes.
“A future in which cigarettes are obsolete is within reach. In fact, with the right regulatory encouragement and support from civil society, we believe cigarette sales can end within 10 to 15 years in many countries. Yes, that’s right: an end to cigarettes within 10 to 15 years in many countries.
“Unfortunately, political agendas and ideology are slowing progress and keeping millions of people uninformed. Rather than holding an evidence-based conversation on how best to regulate these innovative products to help adult smokers leave cigarettes behind, we are often faced with an ideologically driven resistance from some public health organizations and some NGOs. These organizations allow disinformation to appear as legitimate science. They put dogma before data, and they expend more energy on attacking a company than on helping the human beings who should be at the center of the debate.
“Poorly executed scientific studies, skewed results shaped by bias, and misleading media headlines are now the norm.
“What is the result? Many adults who smoke are confused about these better alternatives and so continue to use cigarettes—the most harmful way of consuming nicotine. This is inexcusable. We must ask: Who will take responsibility for denying these adults access to and accurate information about science-backed innovations? Who will be held responsible for the real-world consequences of dogmatic thinking?
“The issues created by uncertainty, polarization, hyperpartisanship, and ideology are not unique to the tobacco sector. From climate change to food security, we need fact-based conversations and a collaborative, multinational, multi-stakeholder approach to deliver real change. The public has a right to decision-making and information based in science. We cannot allow politically driven, well-funded individuals to prevent the world’s citizens from learning about and accessing smart solutions. Whether we are talking about vaccines, carbon emissions, or tobacco harm reduction, we need science, not rhetoric, to inform policies and regulations.
“Science unites. It has the power to open borders and minds and bring progress. It can propel innovation.
“For Philip Morris International, science has changed our company and is transforming our industry. I am proud to come before you today to say that, already, more than 11.2 million people have switched to our main smoke-free product and stopped smoking . Many more have switched to other smoke-free alternatives that are better than continued smoking. This is a profound public health achievement.
“Governments across the world—in Greece, New Zealand, the United Kingdom, and beyond—are beginning to validate the role better alternatives to continued smoking can play. Earlier this year, the U.S. Food and Drug Administration authorized our electronically heated tobacco system, IQOS , as a modified risk tobacco product. In doing so, the agency found that an exposure modification order is ‘appropriate to promote the public health .’
“But a smoke-free future is not yet guaranteed. Ridding the world of cigarettes will require adherence to science, objectivity, collaboration, and a commitment to accelerate information to the people most directly concerned.
“Many years ago, our industry was challenged to create a better alternative to cigarettes. PMI answered that call. We have transformed our entire company to devise and produce scientifically substantiated better products with the aim of delivering a smoke-free future. Science, data, and fact have led us here.
“People who smoke are responding to our efforts. With the right regulations and related information, they could switch out of cigarettes much faster. Let’s put these people—not politics—at the center of policymaking.
“Science secures progress. It secures solutions. It brings hope at a time when global challenges are so great they threaten to overwhelm. We should not allow science to be politicized and polarized.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2020, PMI estimates that approximately 11.2 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 57 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Menicon’s Largest Malaysia Plant Begins Commercial Production5.2.2026 10:00:00 CET | Press release
- Strengthening Global Production Capacity for the Rapidly Growing 1-Day Lens Market Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127294120/en/ The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses. As global demand for 1-DAY lenses continues rising and the industry faces widespread supply constraints, Menicon has made significant capital investments to expand production capacity—even amid the uncertainties presented by the COVID-19 pandemic. Construction of phase 1, currently underway, will provide capacity for up to 500 million lenses per year. The construction plan i
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 09:00:00 CET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
